Private Capital Advisors Inc. Increases Position in Johnson & Johnson (NYSE:JNJ)

Private Capital Advisors Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 36.3% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,005 shares of the company’s stock after buying an additional 2,398 shares during the quarter. Private Capital Advisors Inc.’s holdings in Johnson & Johnson were worth $1,266,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in Johnson & Johnson by 1.5% during the 1st quarter. Geode Capital Management LLC now owns 38,965,156 shares of the company’s stock valued at $5,100,421,000 after buying an additional 572,077 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Johnson & Johnson by 10.8% in the first quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock worth $4,006,895,000 after buying an additional 2,968,879 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Johnson & Johnson by 7.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock worth $3,871,753,000 after acquiring an additional 2,118,870 shares during the last quarter. Capital World Investors grew its stake in Johnson & Johnson by 182.9% during the first quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock valued at $2,779,435,000 after acquiring an additional 13,703,905 shares in the last quarter. Finally, Morgan Stanley increased its holdings in Johnson & Johnson by 0.3% in the 1st quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock valued at $2,727,694,000 after acquiring an additional 54,563 shares during the last quarter. Institutional investors own 68.44% of the company’s stock.

JNJ stock opened at $145.76 on Friday. The stock has a market cap of $383.76 billion, a PE ratio of 21.31, a P/E/G ratio of 3.23 and a beta of 0.69. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The company has a 50-day moving average price of $144.04 and a 200 day moving average price of $144.14. The company has a current ratio of 1.25, a quick ratio of 1.05 and a debt-to-equity ratio of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The business had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.58 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 7.85 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a yield of 2.77%. The ex-dividend date of this dividend is Monday, August 24th. Johnson & Johnson’s payout ratio is currently 46.54%.

A number of brokerages have recently weighed in on JNJ. UBS Group lowered Johnson & Johnson from a “buy” rating to a “neutral” rating and cut their price objective for the company from $163.00 to $160.00 in a research report on Tuesday, April 28th. Wells Fargo & Co upgraded Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Barclays upped their price objective on Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a report on Wednesday, April 29th. Stifel Nicolaus increased their target price on Johnson & Johnson from $140.00 to $155.00 and gave the company a “hold” rating in a research report on Wednesday, April 15th. Finally, Credit Suisse Group restated a “buy” rating and issued a $161.00 price target on shares of Johnson & Johnson in a research report on Tuesday, April 28th. Two analysts have rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $163.38.

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the sale, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: The basics of gap trading strategies

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.